1Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer ( SCLC ) : What have we learned so far[J]? Cancer Treat Rev, 2007, 33:391-406.
2Lloyd KP, Krystal GW. Role of small molecular kit receptor tyro- sine kinase inhibitors in treatment of small-cell lung cancer[ J]. Clin Lung Cancer, 2002,3:213-218.
3Johnson BE, Fischer T, Fischer B, et al. Phase Ⅱ study of imatinib in patients with small cell lung cancer [ J ]. Clin Cancer Res, 2003, 9:5880-5887.
4Dy GK, Miller AA, Mandrekar SJ, et al. A phase Ⅱ trial of ima-tinib ( STI571 ) in patients with c-kit expressing relapsed small cell lung cancer (SCLC)[J]. Ann Oncol, 2005, 16:1811- 1816.
6Schneider B, Gadgeel S, Ramnth N, et al. Phase Ⅱ trail of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC) [ J ]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I), 2006,24, (18S) :Abstraet 17089.
7Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carbopl- atin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase Ⅱ trial of the Minnie Pearl Cancer Research Net- work[J]. J Thorac Oncol, 2007, 2:854-861.
8Warshamana-Greene GS, Litz J, Buchdunger E,et al. The insulin-like growth factor-I ( IGF-I ) receptor kinase inhibitor NVP- ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling[ J]. Mol Cancer Ther, 2004,3:527-536.
9Warshamana-Greene GS, Litz J, Buchdunger E,et al. The insulin-like growth factor-I ( IGF-I ) receptor kinase inhibitor NVP- ADW742, sensitizes small cell lung cancer cell lines to the effects chemotherapy [ J ]. Clin Cancer Res, 2005,11 : 1563-1571.
10Moore AM, Einhorn LH, Esres D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancer: a Hoosier Oncology Group phase Ⅱ trial[J]. Lung Cancer, 2006, 52 : 93 -97.
6Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive smallcell lung cancer[J].N Engl J Med,2002,346:85-91.
7Hanna N,Bunn PA,Langer C,et al.Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J].J Clin Oncol,2006,24:2038-2043.
8Lara PN J,Gandara DR,Natale RB,et al.Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer[J].Clin Lung Cancer,2006,7:353-356.
9Noda K,Nishiwaki Y,Kamahara I,et al.Irinotecan plus cisplatin compared with etopo-side plus cisplatin for extensive small cell lung cancer[J].N Engl J Med,2002,346:85-91.
10Simon GR,Turrisi A;American College of Chest Physicians.Management of small cell lung cancer:ACCP evidence-based clinical practice guidelines(2nd edition)[J].Chest,2007,132:324S-339S.
